Xanadu Bio, Inc. filed a Form D with the Securities and Exchange Commission on 2025-08-27.
Xanadu Bio, Inc. filed a Form D notice of an exempt securities offering with the SEC on August 27, 2025. The filing reports $11M sold. Its industry group is Biotechnology. It names Bruce Turner (Dr. Turner is the Chief Executive Officer, President, Treasurer and Secretary of the Issuer.), Todd Wider (Dr. Wider is the Chief Medical Officer of the Issuer.), Mark Saltzman (Director) (SEC Form D, August 27, 2025).
Is this your company?
Sell to companies like Xanadu Bio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-08-27 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Xanadu Bio, Inc.
Free to see. No signup.
More on the people and the money behind Xanadu Bio, Inc., from the filings we hold.
Biotechnology raises by companies based in Pennsylvania, filed within 90 days of this one, largest first.
Get an email when Xanadu Bio, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Xanadu Bio, Inc. raises, hires or launches. No email unless you switch it on.
Watch Xanadu Bio, Inc. →Get the full cited report on Xanadu Bio, Inc.
What the filing shows about Xanadu Bio, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Xanadu Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Xanadu Bio, Inc.'s address as 980 Idlewild Road, Gladwyne, PA 19035.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Xanadu Bio, Inc. is a registered filer with the SEC (CIK 1946059) and has filed since 2022-12-27. 2 filings are on record, the latest on 2025-08-27.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Xanadu Bio, Inc.'s Form D of 2025-08-27 names Bruce Turner, Todd Wider, Mark Saltzman and 1 more as its officers, directors or promoters.
Its new offerings report $23M sold across 2 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 766 filings in Biotechnology, totalled by week.
On the filing as: Director, Executive Officer, Promoter.
Bruce Turner is named as Dr. Turner is the Chief Executive Officer, President, Treasurer and Secretary of the Issuer. on the Form D that Xanadu Bio, Inc. filed with the SEC on 27 August 2025, one of 4 people that filing names.
On the filing as: Director, Executive Officer, Promoter.
Todd Wider is named as Dr. Wider is the Chief Medical Officer of the Issuer. on the Form D that Xanadu Bio, Inc. filed with the SEC on 27 August 2025, one of 4 people that filing names.
Mark Saltzman is named as Director on the Form D that Xanadu Bio, Inc. filed with the SEC on 27 August 2025, one of 4 people that filing names.
On the filing as: Executive Officer.
Taylor Feehley is named as Dr. Feehley is the Chief Operating Officer of the Issuer. on the Form D that Xanadu Bio, Inc. filed with the SEC on 27 August 2025, one of 4 people that filing names.
4 people named on the filing — 3 holding an executive role and 1 as a director only.
Named as of the 2025-08-27 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Xanadu Bio, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Xanadu Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Xanadu Bio, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Xanadu Bio, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Xanadu Bio, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Xanadu Bio, Inc.. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/xanadu-bio-inc-form-d-25000001